Cantor Fitzgerald set a $13.00 price objective on Axsome Therapeutics (NASDAQ:AXSM) in a research note issued to investors on Friday morning. The brokerage currently has a buy rating on the stock.

Separately, Zacks Investment Research raised shares of Axsome Therapeutics from a hold rating to a buy rating and set a $5.25 target price on the stock in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Axsome Therapeutics has a consensus rating of Buy and an average price target of $16.70.

Axsome Therapeutics (AXSM) opened at $5.27 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.86 and a quick ratio of 3.86. Axsome Therapeutics has a 12-month low of $3.53 and a 12-month high of $7.20.

Several large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its holdings in shares of Axsome Therapeutics by 1.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,459,117 shares of the company’s stock valued at $8,026,000 after buying an additional 23,229 shares in the last quarter. Sphera Funds Management LTD. boosted its holdings in shares of Axsome Therapeutics by 24.9% in the 2nd quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after buying an additional 100,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Axsome Therapeutics by 118.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock valued at $372,000 after buying an additional 36,698 shares in the last quarter. LMR Partners LLP bought a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at about $206,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at about $188,000. Institutional investors and hedge funds own 25.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-reiterates-13-00-price-target-for-axsome-therapeutics-axsm/1742920.html.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Receive News & Ratings for Axsome Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.